A Prospective, Randomized, Open Label, Single-Centre Study for Assessment of Safety and Effectiveness of Recombinant Human Insulin 30/70 + Insulin Glulisine compared to Recombinant Human Insulin NPH + Regular in the Management of Type 2 Diabetes Mellitus Patients in the Philippines.